Therefore, these results indicated that AQP1 is an important mediator of septic AKI and that pharmacological targeting of AQP1 mediated P53 signaling may provide a novel approach for the prevention or treatment of septic AKI. This evidence concerns the gene AQP1 and acute kidney injury.